COMPANY PROFILE

ADOCIA

Innovative medicine for everyone, everywhere (diabetes, metabolic diseases)

Lyon, FranceFounded 2005Biotech & Life Sciences

Valuation $87M Market cap · 2026

Revenue $2.5M Latest reported FY

About ADOCIA

Adocia is a clinical-stage biotechnology company specializing in the development of innovative formulations for protein delivery, primarily targeting diabetes treatment. The company operates in the healthcare and biotechnology sectors, focusing on creating advanced injectable treatments. Adocia customizes its proprietary BioChaperone technology to enhance the efficacy and safety of therapeutic proteins. The company serves pharmaceutical and healthcare clients, aiming to improve patient outcomes through innovative drug formulations. Adocia generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The business model is centered on research and development, leveraging its extensive portfolio of clinical-stage products to attract strategic collaborations and funding.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2005
Headquarters: Lyon, France
Listing: IPO 2012
Employees: 92
Open positions: 1
Dealroom signal: 73.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Diabetes, Biotechnology, Drug Development, Alternative Protein, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech, proteomics
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	Apr 2026	$0	—	Undisclosed	↗
POST IPO EQUITY✓Other financing	Dec 2025	$11M	—	Undisclosed	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$2.5M	+55.3%	−$17M	-670.8%	−$18M	-724.2%	$5.5M
2025	$1.6M	-84.2%	−$17M	-1041.8%	−$18M	-1124.8%	$5.5M
2024	$10M	+333.5%	−$7.6M	-74.2%	−$10M	-100%	$5.5M
2023	$2.4M	-81.2%	−$15M	-640.3%			$5.5M
2022	$13M	+692.7%	−$1.3M	-10.2%
2021	$1.6M	+71.7%	−$20M	-1249.4%
2020	$925K	—	−$22M	-2407.1%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ADOCIA website traffic

Latest recorded traffic for ADOCIA is 4.9K monthly website visits, up 2.1% over the last three months. ADOCIA's team grew 3.4% over the past year.

Latest monthly visits4.9K 3-month web change+2.1% 1-year team growth+3.4%

Monthly website visitsDec 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ADAdipoPharmaDevelopment of a first-in-class drug for type 2 diabetes, targeting adipocyte cells to reverse insulin resistance	Strasbourg, France	Operational	7	$17M	$66M
ALAlbupadDeveloping 100% protein-based materials for biomedical applications	Illkirch, France	Operational
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
VAVAXXELVaxxel develops novel and proprietary live-attenuated vaccines candidate against respiratory infections	Villeurbanne, France	Operational
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
DIDiogenXBeta-Cell recovery to counter diabetes	Marseille, France	Operational
AFAelis FarmaBiotech company conducting research and development on innovative signaling specific drugs	Bordeaux, France	Operational
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational